• SAR405: A Precision Vps34 Inhibitor Workflow

  2026-08-27

  SAR405 enables direct, selective interrogation of Vps34-dependent PI3P production alongside upstream AMPK–ULK1 signaling. This workflow combines dose-controlled autophagy inhibition, vesicle trafficking modulation, and lysosome function impairment with practical controls for starvation and mTOR-inhibitor experiments.

• TMRE and Mitochondrial Energy Failure

  2026-08-26

  A translational framework for using TMRE fluorescence to connect sodium-driven mitochondrial dysfunction with ΔΨm loss, apoptosis research, and reproducible mitochondrial function analysis.

• Podophyllotoxin Derivative 5p Overcomes MDR

  2026-08-26

  The reference study shows that podophyllotoxin derivative 5p combines catalytic topoisomerase IIα inhibition with suppression of microtubule polymerization, producing activity in multidrug-resistant cancer models. Its effects include transporter downregulation, G2/M arrest, apoptosis, pyroptosis-associated damage, and reduced xenograft growth, making the compound a useful mechanistic lead for anticancer drug research.

• GW 6471 Workflows for PPARα Research

  2026-08-25

  GW 6471 is a practical PPARα antagonist for testing whether receptor activity links chemical exposure to lipid imbalance and liver injury. This guide translates zebrafish evidence into controlled workflows for cellular metabolism research, lipid homeostasis studies, and PPARα-related disease modeling.

• PD98059: Reading ERK Signals in Injury Models

  2026-08-25

  PD98059 is a selective and reversible MEK inhibitor for testing whether ERK signaling drives oxidative stress, mitochondrial apoptosis, and cell-cycle changes. This article presents a causal assay framework built around cyclophosphamide-induced liver injury and explains how to interpret PD98059 across cancer and ischemia research.

• TCAIM Control of OGDH and Mitochondrial Metabolism

  2026-08-24

  A 2025 Molecular Cell study identifies TCAIM as a mitochondrial DNAJC co-chaperone that selectively binds native OGDH and promotes its reduction through HSPA9 and LONP1. The work reveals that mitochondrial proteostasis can directly tune a rate-limiting metabolic enzyme, suppressing OGDH complex activity and reshaping carbohydrate catabolism in cells and mice.

• Cryptosporidium AdhE as an Antifungal-Imidazole Target

  2026-08-23

  The reference study identifies the bacterial-type bifunctional aldehyde/alcohol dehydrogenase AdhE as a chemically tractable metabolic target in Cryptosporidium parvum. Screening and cellular follow-up showed that several antifungal imidazoles inhibit CpAdhE and suppress parasite growth in vitro, supporting further target-based anti-cryptosporidial research while leaving important questions about selectivity and in vivo activity unresolved.

• Tetrandrine: An Assay-Design Framework

  2026-08-22

  Tetrandrine is more than a calcium-channel modulator: it is a useful probe for building evidence-aware assays across ion channel, inflammation, neuroscience, and cancer biology research. This guide connects compound handling, mechanistic readouts, and structure-based screening without overstating translational evidence.

• Phenacetin in Human-Relevant PK Research

  2026-08-21

  A translational perspective on using Phenacetin as a mechanistically informative research probe in human intestinal organoid workflows, with practical guidance on solubility, assay design, model selection, safety interpretation, and experimental rigor.

• IPA-3: A Decision Framework for Pak1 Assays

  2026-08-21

  IPA-3 is a non-ATP-competitive Pak1 inhibitor for resolving regulatory kinase biology. This evidence-led guide explains how to interpret Pak1 autophosphorylation inhibition, select assay formats, and use negative results across disease models.

• Regorafenib (BAY 73-4506) Assay Guide

  2026-08-20

  A scenario-based guide to using Regorafenib (BAY 73-4506), SKU A8236, in viability, proliferation, migration, and invasion workflows. It connects kinase potency, solvent handling, exposure design, melanoma evidence, and vendor-selection criteria to improve experimental interpretability.

• Enhanced MSA-2 Immunotherapy with Circular IL-23 mRNA

  2026-08-19

  The reference study developed LNP36 to deliver circular IL-23 mRNA locally and combined this platform with platinum-modified MSA-2, a STING agonist, in a B16F10 melanoma model. The combination increased tumor control and survival after intratumoral administration, highlighting how local cytokine expression and chemical optimization of a STING agonist can be integrated into one immunotherapy strategy.

• PD98059 in Vascular MAPK/ERK Research

  2026-08-19

  PD98059 is a selective MEK inhibitor for testing MAPK/ERK-dependent biology. This article explains how the compound helped connect nanoplastic exposure with vascular lipid dysregulation and shows how to design stronger pharmacological and genetic validation assays.

• Mildronate-Derived Lipidoids for Safer mRNA Delivery

  2026-08-18

  The ACS Nano study developed mLNP-69, a low-dose mildronate-derived cationic lipid nanoparticle that preserved effective mRNA delivery while reducing local inflammation relative to an SM102-based comparator. Its performance in prophylactic and therapeutic B16OVA melanoma models supports a formulation strategy that separates delivery potency from inflammatory burden, although broader validation is still required.

• Cryptosporidium AdhE: Imidazole Inhibition and Efficacy

  2026-08-18

  The reference study identifies the bacterial-type bifunctional aldehyde/alcohol dehydrogenase CpAdhE as a chemically vulnerable metabolic target in Cryptosporidium parvum. Screening, enzyme kinetics, parasite-growth assays, and cytotoxicity testing together showed that several antifungal imidazoles inhibit CpAdhE and suppress parasite growth at lower micromolar concentrations, providing a rationale for target-directed antiparasitic discovery.

456 records 7/31 page Previous Next First page 上5页 678910 下5页 Last page